AAAAAA

   
Results: 1-9 |
Results: 9
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma
Authors: Skobe, M Hamberg, LM Hawighorst, T Schirner, M Wolf, GL Alitalo, K Detmar, M
Citation: M. Skobe et al., Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma, AM J PATH, 159(3), 2001, pp. 893-903
Antiangiogenic chemotherapeutic agents
Authors: Schirner, M
Citation: M. Schirner, Antiangiogenic chemotherapeutic agents, CANC METAST, 19(1-2), 2000, pp. 67-73
A novel function for the tumor suppressor p16(INK4a): Induction of anoikisvia upregulation of the alpha(5)beta(1) fibronectin receptor
Authors: Plath, T Detjen, K Welzel, M von Marschall, Z Murphy, D Schirner, M Wiedenmann, B Rosewicz, S
Citation: T. Plath et al., A novel function for the tumor suppressor p16(INK4a): Induction of anoikisvia upregulation of the alpha(5)beta(1) fibronectin receptor, J CELL BIOL, 150(6), 2000, pp. 1467-1477
De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop
Authors: Von Marschall, Z Cramer, T Hocker, M Burde, R Plath, T Schirner, M Heidenreich, R Breier, G Riecken, EO Wiedenmann, B Rosewicz, S
Citation: Z. Von Marschall et al., De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop, GASTROENTY, 119(5), 2000, pp. 1358
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
Authors: Wood, JM Bold, G Buchdunger, E Cozens, R Ferrari, S Frei, J Hofmann, F Mestan, J Mett, H O'Reilly, T Persohn, E Rosel, J Schnell, C Stover, D Theuer, A Towbin, H Wenger, F Woods-Cook, K Menrad, A Siemeister, G Schirner, M Thierauch, KH Schneider, MR Drevs, J Martiny-Baron, G Totzke, F Marme, D
Citation: Jm. Wood et al., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, CANCER RES, 60(8), 2000, pp. 2178-2189
Inhibition of VEGF receptor tyrosine kinase
Authors: Siemeister, G Menrad, A Schirner, M Thierauch, KH Schneider, MR Martiny-Baron, G Marme, D Bold, G Rosel, J Wood, JM
Citation: G. Siemeister et al., Inhibition of VEGF receptor tyrosine kinase, ANGIOGENESIS IN HEALTH AND DISEASE, 2000, pp. 339-348
Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF
Authors: Piossek, C Schneider-Mergener, J Schirner, M Vakalopoulou, E Germeroth, L Thierauch, KH
Citation: C. Piossek et al., Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF, J BIOL CHEM, 274(9), 1999, pp. 5612-5619
Two independent mechanisms essential for tumor angiogenesis: Inhibition ofhuman melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
Authors: Siemeister, G Schirner, M Weindel, K Reusch, P Menrad, A Marme, D Martiny-Baron, G
Citation: G. Siemeister et al., Two independent mechanisms essential for tumor angiogenesis: Inhibition ofhuman melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway, CANCER RES, 59(13), 1999, pp. 3185-3191
Integrin alpha 5 beta 1: a potent inhibitor of experimental lung metastasis
Authors: Schirner, M Herzberg, F Schmidt, R Streit, M Schoning, M Hummel, M Kaufmann, C Thiel, E Kreuser, ED
Citation: M. Schirner et al., Integrin alpha 5 beta 1: a potent inhibitor of experimental lung metastasis, CLIN EXP M, 16(5), 1998, pp. 427-435
Risultati: 1-9 |